Reata Pharmaceuticals PEG Ratio

Reata Pharmaceuticals (RETA) currently reports a PEG ratio of 5.54. That is above the Healthcare sector average of 2.56. Use the charts on this page to explore Reata Pharmaceuticals's PEG ratio history and peer comparisons.

Reata Pharmaceuticals's PEG ratio of 5.54 is higher than the Healthcare sector average of 2.56. That is roughly 116.3% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The PEG ratio is a valuation multiple that relates Reata Pharmaceuticals's market price to a fundamental measure such as earnings, sales, or book value. At 5.54, RETA can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current PEG ratio of 5.54, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 2.56. From there, open related valuation or income-statement pages for Reata Pharmaceuticals, and consider following RETA for alerts when major investors trade the stock.

Reata Pharmaceuticals is classified in the Healthcare sector. On PEG ratio, it currently shows 5.54 versus a sector average near 2.56. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing RETA with unrelated industries.